IMARC Group's report titled “Cancer Biomarkers Market Report by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetics), Biomolecule (Genetic Biomarkers, Protein Biomarkers, Glyco-Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, and Others), Application (Diagnostics, Prognostics, Risk Assessment, Drug Discovery and Development, and Others), End User (Hospitals, Academic and Research Institutions, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others), and Region 2024-2032”. offers a comprehensive analysis of the industry, which comprises insights on the global cancer biomarkers market trends. The global market size reached US$ 27.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 77.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.7% during 2024-2032.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/cancer-biomarkers-market/requestsample
Factors Affecting the Growth of the Cancer Biomarkers Industry:
- Increasing Incidence of Cancer:
With cancer rates rising, there is a heightened emphasis on early detection to improve treatment outcomes. Biomarkers play a crucial role in this by enabling more accurate and timely diagnosis. Biomarker tests can detect cancer at earlier stages when treatment is more effective, thereby driving the demand for biomarker-based diagnostic tools. Moreover, biomarkers are also used to monitor cancer progression and assess treatment response. As the number of cancer cases is increasing, there is a growing need for biomarkers that can accurately monitor disease progression and predict patient outcomes. This is driving research and development (R&D) activities to identify and validate biomarkers associated with different cancer types.
- Technological Advancements:
Innovations in technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR)-based assays, and digital pathology, are significantly improving the sensitivity and specificity of biomarker detection. This allows for the identification of biomarkers that were previously undetectable or difficult to measure, enhancing diagnostic accuracy. Furthermore, technologies like NGS enable high-throughput screening of genetic mutations, gene expression patterns, and epigenetic changes associated with cancer and accelerate biomarker discovery efforts by allowing researchers to analyze large volumes of genetic data quickly and cost-effectively.
- Rising Demand for Personalized Medicine:
Personalized medicine aims to tailor treatments based on individual patient characteristics, including genetic, molecular, and biomarker profiles. Biomarkers play a crucial role in identifying specific genetic mutations, protein expressions, or other molecular features associated with patient cancer. This enables oncologists to select targeted therapies that are more likely to be effective against the tumor, leading to improved treatment outcomes. In addition, biomarker-guided therapy allows for more precise targeting of cancer cells while minimizing damage to healthy tissues. This approach increases treatment efficacy and reduces the likelihood of adverse effects compared to traditional, non-personalized treatment approaches.
Leading Companies Operating in the Global Cancer Biomarkers Industry:
- Abbott Laboratories
- Agilent Technologies Inc.
- Becton Dickinson and Company
- bioMérieux SA
- Danaher Corporation
- F. Hoffmann-La Roche AG
- General Electric Company
- Illumina Inc.
- Qiagen N.V.
- Sino Biological Inc.
- Thermo Fisher Scientific Inc.
Cancer Biomarkers Market Report Segmentation:
By Profiling Technology:
- Omic Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics
On the basis of the technology, the market has been divided into omic technologies, imaging technologies, immunoassays, and cytogenetics.
By Biomolecule:
- Genetic Biomarkers
- Protein Biomarkers
- Glyco-Biomarkers
Genetic biomarkers account for the majority of the market share due to their pivotal role in understanding and treating cancer at a molecular level.
By Cancer Type:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
Lung cancer holds the biggest market share owing to its growing prevalence, diagnosis, and treatment.
By Application:
- Diagnostics
- Prognostics
- Risk Assessment
- Drug Discovery and Development
- Others
Based on the application, the market has been classified into diagnostics, prognostics, risk assessment, drug discovery and development, and others.
By End User:
- Hospitals
- Academic and Research Institutions
- Ambulatory Surgical Centers
- Diagnostic Laboratories
- Others
Based on the end user, the market has been categorized into hospitals, academic and research institutions, ambulatory surgical centers, diagnostic laboratories, and others.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position in the cancer biomarkers market on account of advanced healthcare infrastructure and a robust research and development (R&D) activities.
Global Cancer Biomarkers Market Trends:
Artificial intelligence (AI) algorithms and machine learning (ML) models analyze complex biomarker data sets. These technologies can identify subtle patterns and correlations in biomarker profiles that may not be apparent through traditional methods, leading to more accurate predictions of disease outcomes and treatment responses.
In addition, advancements in bioinformatics tools and software platforms support the integration, analysis, and interpretation of large-scale biomarker data. These tools enable researchers to extract meaningful insights from complex datasets, facilitating biomarker discovery and clinical translation.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
